Literature DB >> 7994805

Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

N S Kleiman1, H D White, E M Ohman, A M Ross, L H Woodlief, R M Califf, D R Holmes, E Bates, M Pfisterer, A Vahanian.   

Abstract

BACKGROUND: A paradoxical increased risk of death has been reported during the first 24 hours after thrombolysis for myocardial infarction. The mechanism of this phenomenon is not known, nor is its relation to the success or failure of reperfusion. The present study was a prospectively designed analysis of deaths occurring within the first 24 hours in the GUSTO trial. METHODS AND
RESULTS: There were 41,021 patients enrolled in GUSTO, a randomized comparison of streptokinase with intravenous or subcutaneous heparin, accelerated tissue-type plasminogen activator (TPA), and combination of streptokinase and TPA. An angiographic mechanistic substudy examined reperfusion (using the TIMI flow grading criteria) 90 minutes after the assigned thrombolytic regimen was begun in 1567 patients. There were 1125 deaths (2.8%) within 24 hours ("early deaths") and 1726 additional deaths (4.2%) after 24 hours but within 30 days ("later deaths"). At the time of presentation, the most potent predictors of early death were hypotension and sinus tachycardia. In a multiple logistic regression model, lower systolic blood pressure, shorter height, higher heart rate, and the absence of prior smoking distinguished early death from later death. Reinfarction occurred in 26 patients (2.4%), shock in 572 patients (52%), atrioventricular block in 308 patients (28%), and tamponade in 106 patients (10%) dying early compared with 262 (15%), 788 (46%), 396 (23%), and 74 (4%) respective patients dying later. There were no differences in early mortality among the thrombolytic regimens for the first 6 hours after randomization. By 24 hours, however, mortality was 2.89% for streptokinase recipients, 2.84% for combination therapy recipients, and 2.36% for accelerated TPA recipients (P = .005). There was little difference among patients with differing flow grades in the infarct artery during the first 4 hours, although mortality was 2.35% for patients with flow grade 0 or 1, 2.92% for patients with flow grade 2, and 0.89% for patients with flow grade 3.
CONCLUSIONS: Even with aggressive management regimens, mortality within the first 24 hours accounted for a large proportion of postthrombolytic deaths. Patients dying early were more likely to present with pump failure than were those dying later and were more likely to diet of events related to left ventricular dysfunction, although cardiac tamponade also accounted for a significant minority of these deaths. Thus, the severity of the clinical presentation rather than the underlying risk factors predicts early mortality. Based on the angiographic substudy data, it appears that rather than hastening early mortality, successful restoration of complete antegrade flow in the infarct-related artery protects against early death.

Entities:  

Mesh:

Year:  1994        PMID: 7994805     DOI: 10.1161/01.cir.90.6.2658

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Electrocardiographic ST segment elevation in adults with chest pain.

Authors:  W J Brady; F Morris
Journal:  J Accid Emerg Med       Date:  1999-11

2.  Three-dimensional structure of fibrolase, the fibrinolytic enzyme from southern copperhead venom, modeled from the X-ray structure of adamalysin II and atrolysin C.

Authors:  M B Bolger; S Swenson; F S Markland
Journal:  AAPS PharmSci       Date:  2001

3.  Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven/Proven the Thrombin Hypothesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

4.  The Open-Artery Hypothesis: An Overview.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

5.  Implications of the GUSTO trial for thrombolytic therapy.

Authors:  F Van de Werf
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 6.  Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.

Authors:  L B Barradell; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

7.  Association Between Body Weight and In-Hospital Clinical Outcome Following Thrombolytic Therapy: A Report from the National Registry of Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 8.  [Thrombolysis in ST-elevation myocardial infarction. Current role in the light of recent studies].

Authors:  H-R Arntz; U Zeymer; P Schwimmbeck
Journal:  Anaesthesist       Date:  2004-05       Impact factor: 1.041

9.  Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy.

Authors:  Gjin Ndrepepa; Dritan Keta; Stefanie Schulz; Robert A Byrne; Julinda Mehilli; Jürgen Pache; Melchior Seyfarth; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2009-09-10       Impact factor: 5.460

10.  Influence of thrombolytic therapy on the patterns of ventricular septal rupture after acute myocardial infarction.

Authors:  G R Rhydwen; S Charman; P M Schofield
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.